TY - JOUR T1 - 84 Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in advanced peritoneal carcinomatous (APC) at the american university of beirut medical center (AUBMC): a retrospective review JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A44 LP - A44 DO - 10.1136/ijgc-2019-IGCS.84 VL - 29 IS - Suppl 3 AU - M Seoud AU - A El Housheimi AU - A Shamseddine AU - M Khalifeh AU - I Jaafar AU - F Jamali Y1 - 2019/09/01 UR - http://ijgc.bmj.com/content/29/Suppl_3/A44.abstract N2 - Objectives To review the outcome of patients with APC who underwent CRS+HIPEC by the HIPEC team at the AUBMC.Methods All patients with APC were evaluated by the HIPEC team for eligibility and the majority had either gastrointestinal or gynecological malignancies. We retrospectively reviewed data related to their demographics/tumor origin/surgical completeness/adverse events/outcome.Results between 2007 and 2018, 53 patients (45% were females) had CRS and HIPEC. 20 (37.6%) had Pseudomyxoma peritonei (PMP), 12 (23%) ovarian cancer, 14 (26.4%) colorectal cancer, 4 (7.5%) had gastric cancer, 2 (3.7%) had Mesothelioma and one (1.8%) Desmoplastic round cell tumor. Operative and Postoperative demographics and survivals are shown in tables 1 and 2. Median progression free (PFS) and overall survival (OS) are expressed in months.View this table:Abstract 84 Table 1 Operative and postoperative dataView this table:Abstract 84 Table 2 Survival dataConclusions We report the successful establishment of an active peritoneal surface malignancy multidisciplinary treatment program with results comparable to other centers. Careful patient selection, a multidisciplinary approach and proper surgical training and technique are essential for the success of such a program. ER -